Tirzepatide trial to evaluate reduction of atrial fibrillation recurrence in obese HFpEF patients
Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF
Abstract
Tirzepatide will be evaluated in a 602-participant trial for its ability to reduce atrial fibrillation recurrence after ablation in obese HFpEF patients.